Drug delivery technologies have enabled the development of many pharmaceutical
products that improve patient health by enhancing the delivery of a therapeutic to its target …

Attention-deficit/hyperactivity disorder (ADHD) is commonly associated with disordered or
disturbed sleep. The relationships of ADHD with sleep problems, psychiatric comorbidities …

Background Attention deficit–hyperactivity disorder (ADHD) is a common disorder that has
been associated with criminal behavior in some studies. Pharmacologic treatment is …

Objectives: To identify the relationship between the core Diagnostic and Statistical Manual of
Mental Disorders (5th ed.) ADHD symptoms and executive function deficits (EFDs), to …

Background There are persistent concerns of long‐term effects of stimulant ADHD
medication on the development of substance abuse. Methods Using Swedish national …

Context More than 1.5 million US adults use stimulants and other medications labeled for
treatment of attention-deficit/hyperactivity disorder (ADHD). These agents can increase heart …

Aim To test the efficacy and safety of osmotic release oral system (OROS) methylphenidate
(MPH) in doses up to 180 mg/day to treat attention deficit hyperactivity disorder (ADHD) and …

Background: The efficacy of methylphenidate for adults with attention-deficit hyperactivity
disorder (ADHD) shows wide between-study variability, which yields heterogeneous results …

Background Attention deficit hyperactivity disorder (ADHD) affects approximately 3% of
adults globally. Many pharmacologic treatments options exist, yet the comparative benefits …

Attention-deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder
characterized by persistent symptoms of inattention, hyperactivity and/or impulsivity. The …